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A B S T R A C T
The reproducibility of plasma protein quantitation between laboratories and between instrument types
was examined in a large-scale international study involving 16 laboratories and 19 LC–MS/MS platforms,
using two kits designed to evaluate instrument performance and one kit designed to evaluate the entire
bottom-up workﬂow. There was little effect of instrument type on the quality of the results,
demonstrating the robustness of LC/MRM-MS with isotopically labeled standards. Technician skill was a
factor, as errors in sample preparation and sub-optimal LC–MSperformancewere evident. This highlights
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the importance of proper training and routine quality control before quantitation is done on patient
samples.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Reproducible and accurate quantitation is a requirement for
clinical and translational applications in targeted proteomics. The
“gold standard”method inMS-based proteomics relies onmultiple
reaction monitoring (MRM) with stable isotope-labeled standards
(SIS) incorporated within a bottom-up workﬂow [1]. Although
MRM with labeled standards has been used for decades in small-
molecule analysis (e.g., hormones, drugs) [2,3], the use of this
technique in proteomics introduces additional analytical variables
related to sample preparation (e.g., digestion) that increases the
complexity of the sample analysis, thereby increasing the potential
for interferences with the MRM transitions. To address this,
standardization of proteomics methods has been encouraged by
the Human Proteomics Proteome Organization’s Plasma Proteome
Project [4–10] and supported further by the US National Cancer
Institute through the Clinical Proteomic Tumor Analysis Consor-
tium [11,12]. This is necessary to enhance the global reproducibility
of high quality data using different MS technologies.
As part of this standardization effort, we previously developed
three standardization kits for instrument QC on a daily (Kit A) or
monthly (Kits B and C) basis for LC–MS/MS platform (Kits A and B)
and complete workﬂow (Kit C) assessment [13,14]. These kits
contain a set of materials and analysis tools that enable value
tracking and accuracy estimation by comparison with a set of
reference values/ranges. Lyophilized pre-digested plasma stand-
ards that were spikedwith a SIS peptidemixture (43 peptides from
43 human plasma proteins) are provided in Kits A and B, while raw
startingmaterials (namely undepleted plasma, trypsin, and the SIS
mix) are provided in Kit C for sample preparation and subsequent
processing/analysis. In all cases, samples are processed by LC–MS/
MS in a targeted or semi-targeted manner (i.e., by using MRM on a
triple quadrupole mass spectrometer or by using parallel reaction
monitoring (PRM) on a hybrid quadrupole-Orbitrap mass spec-
trometer, respectively). These operative modes differ in that
precursor-product ion pairs (i.e., transitions) are sequentially
monitored in MRM, whereas in PRM, full product ion spectra are
collected from the collisional fragmentation of all target precursors
in a given m/z window (see Fig. 1a and b in [15] for comparative
schematics).
In this paper, we report the use of these three kits to evaluate
the accuracy and reproducibility of a quantitative proteomics
analysis of 43 high-to-moderate abundance plasma proteins in a
bottom-up workﬂow, and to determine the source of errors if sub-
[(Fig._1)TD$FIG]
Fig.1. Experimental workﬂows and starting points for the 3 QC kits. Kits A and B required simple rehydration of the lyophilized peptidemixture(s) prior to sample processing
by LC/MRM-MS or LC/PRM-MS, whereas Kit C required the user to execute the entire workﬂow from 3 supplied starting materials (namely plasma, trypsin, and the SIS mix).
Kit dispersal and data/quantitative analysis were performed at the UVic-Genome BC Proteomics Centre. Quantitationwas facilitated by Qualis-SIS which generated standard
curves (relative response vs. SIS concentration) from the SIS (red trace) and NAT (blue trace) response data of each peptide’s quantiﬁer transition. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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optimal results were obtained. These analyses were performed in
different laboratories and on different instruments as part of an
international multi-laboratory study which involved 15 partici-
pating laboratories and 19 total LC–MS/MS platforms from 4
vendors. Although this study is similar to a recently published
multi-site study [16] in that both involved multiple sites and
instruments from several vendors, there are signiﬁcant differences.
The previous multi-site study used immunodepleted plasma and a
variety of different digestion procedures, with Lys-C/trypsin being
ultimately recommended. In the study reported here, no afﬁnity
depletionwas used. Thus, this current study involved amuchmore
complex matrix. In addition, only trypsin was used for the
digestion of the raw, undepleted, plasma, as Lys-C was deemed to
be too costly for large-scale quantitative proteomics projects.
Importantly, a major focus of our study was to determine the
sources of variability, so that future action could be taken to reduce
these errors.
2. Methods
The methods used are brieﬂy described here with additional
details being provided in Supporting information—Methods.
2.1. Materials, standards, and kit preparation
Forty-three proteotypic tryptic peptides (corresponding to 43
plasma proteins) were originally selected using bioinformatics.
Synthesis of C-terminal [13C] and/or [15N]-labeled analogues of
these proteotypic peptides was performed at the University of
Victoria (UVic)-Genome British Columbia Proteomics Centre using
Fmoc protection chemistry [17] on a Prelude or an Overture
Robotic Peptide Synthesizer (Peptide Technologies; Seattle, WA,
USA). After synthesis, the SIS peptides were puriﬁed by reversed-
phase HPLC using an Agilent 1260 Inﬁnity LC, with the peptides’
identities being subsequently veriﬁed by MALDI-TOF-MS on an
Ultraﬂex III mass spectrometer (Bruker Daltonics; Bremen,
Germany). Characterization was done by amino-acid analysis,
for composition determination, and capillary zone electrophoresis,
for purity. The average purity of these SIS peptides was found to be
95%.
Human plasma was obtained from Bioreclamation (catalog no.
HMPLEDTA2; Westbury, NY, USA). This bioﬂuid represented a
pooled sample collected from a group of healthy, race- and gender-
matched donors between the ages of 18 and 50. The plasma
samples were stored at 20 C until use, in order to reduce
degradation.
“Bond-breaker TCEP solution” (0.5M tris(2-carboxyethyl)
phosphine) was purchased from Thermo Scientiﬁc (Rockford, IL,
Table 1
List of targeted plasma proteins in the QC kit and their reference concentrations, as determined by LC/MRM-MS with SIS peptides.
No. Protein UniProt acc. No. Peptide Reference plasma protein conc. (mg/mL)
1 Afamin P43652 DADPDTFFAK 30.71
2 Albumin_serum P02768 LVNEVTEFAK 34966.77
3 Alpha-1-acid glycoprotein 1 P02763 NWGLSVYADKPETTK 29.13
4 Alpha-1-antichymotrypsin P01011 EIGELYLPK 151.13
5 Alpha-1B-glycoprotein P04217 LETPDFQLFK 262.36
6 Alpha-2-antiplasmin P08697 LGNQEPGGQTALK 3.18
7 Alpha-2-macroglobulin P01023 LLIYAVLPTGDVIGDSAK 96.42
8 Angiotensinogen P01019 ALQDQLVLVAAK 15.58
9 Antithrombin-III P01008 DDLYVSDAFHK 20.67
10 Apolipoprotein A-I P02647 ATEHLSTLSEK 981.56
11 Apolipoprotein A-II P02652 SPELQAEAK 33.52
12 Apolipoprotein A-IV P06727 SLAPYAQDTQEK 21.59
13 Apolipoprotein B-100 P04114 FPEVDVLTK 186.45
14 Apolipoprotein C-I P02654 TPDVSSALDK 0.54
15 Apolipoprotein C-III P02656 GWVTDGFSSLK 1.81
16 Apolipoprotein E P02649 LGPLVEQGR 22.51
17 Beta-2-glycoprotein I P02749 ATVVYQGER 87.89
18 Ceruloplasmin P00450 EYTDASFTNR 42.72
19 Clusterin P10909 ELDESLQVAER 204.69
20 Coagulation factor XII a light chain P00748 VVGGLVALR 9.58
21 Complement C3 P01024 TGLQEVEVK 298.48
22 Complement C4 gamma chain P0C0L5 ITQVLHFTK 93.14
23 Complement C9 P02748 TEHYEEQIEAFK 6.86
24 Complement factor B P00751 EELLPAQDIK 9.84
25 Complement factor H P08603 SPDVINGSPISQK 152.82
26 Fibrinogen alpha chain P02671 GSESGIFTNTK 664.56
27 Fibrinogen beta chain P02675 QGFGNVATNTDGK 177.41
28 Fibrinogen gamma chain P02679 DTVQIHDITGK 2.48
29 Gelsolin P06396 TGAQELLR 7.20
30 Haptoglobin P00738 VGYVSGWGR 1222.73
31 Hemopexin P02790 NFPSPVDAAFR 422.30
32 Heparin cofactor II P05546 TLEAQLTPR 55.23
33 Inter-alpha-trypsin inhibitor heavy chain H1 P19827 AAISGENAGLVR 36.72
34 Kininogen-1 P01042 TVGSDTFYSFK 55.33
35 L-selectin P14151 AEIEYLEK 1.16
36 Retinol-binding protein 4 P02753 YWGVASFLQK 19.23
37 Plasminogen P00747 LFLEPTR 4.89
38 Prothrombin P00734 ETAASLLQAGYK 2.40
39 Serum amyloid P-component P02743 VGEYSLYIGR 0.41
40 Serotransferrin P02787 EDPQTFYYAVAVVK 180.37
41 Transthyretin P02766 AADDTWEPFASGK 70.53
42 Vitamin D-binding protein P02774 THLPEVFLSK 105.72
43 Vitronectin P04004 FEDGVLDPDYPR 35.21
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USA) and TPCK-treated trypsin was obtained from Worthington
(Lakewood, NJ, USA). All remaining chemicals (e.g., ammonium
bicarbonate, dithiothreitol) and solvents (e.g., acetonitrile, metha-
nol)were of analytical reagent or LC/MS grade, andwere purchased
from Sigma–Aldrich (St. Louis, MO, USA).
Three kits were assembled at the UVic-Genome BC Proteomics
Center and distributed at once to the 15 participating laboratories
(see Fig.1 for aworkﬂow schematic). Kits A and Bwere prepared at
the Centre by the addition of a mixture of 43 SIS peptides (from 43
human plasma proteins; see Table 1 for the target panel) to a
plasma tryptic digest, followed by solid phase extraction (10mg
Oasis HLB sorbent;Waters;Milford,MA, USA) and lyophilization of
the eluate. The use of Kit A required rehydration of a pre-digested
plasma standard in 0.1% formic acid. The SIS peptide mixture used
in this kit had previously been concentration-balanced to their
endogenous peptide concentrations found in a pooled, de-
identiﬁed plasma sample. Kit B is similar to Kit A, but required
the addition of varying amounts of the SIS-peptide mixture to a
constant amount of digested plasma, in order to generate 7-point
standard curves spanning a 10,000-fold range (with standards
labeled A–G from lowest to highest concentration). The analytical
workﬂow Kit C contains three starting materials (raw plasma,
trypsin, and the balanced SISmix) for the preparation of the same 7
standard samples that were generated in Kit B.
The reference concentration range for the plasma proteins in
the mixture was from 35mg/mL (for human serum albumin) to
410ng/mL (for serum amyloid P-component; see Table 1), with a
range of protein molecular weights from 7kDa (apolipoprotein C-I,
P02654) to 513kDa (apolipoprotein B-100, P04114) [18]. These kits
were designed to be used with standard-ﬂow and nano-ﬂow LC/
MS/MS platforms, operated in the MRM or PRM modes. Before
distribution of the kits to the participants, the long-term storage
properties and lot-to-lot kit variabilities were determined (see
Supporting information—Fig. 1).
2.2. Study design
The kits were prepared at the Centre and were distributed
simultaneously to the 15 participating laboratories for processing
(see Table 2 for details). The 15 participants in this studywere from
7 different countries, and used 17 LC–MS/MS platforms with 7
different mass spectrometers obtained from 4 different manu-
facturers. Including the 2 reference LC–MS/MS platforms (labeled
R1a and R1b), 68% of the platforms were operated at nano-ﬂow
rates (usually at 300nL/min), while 32% were operated at
standard-ﬂow rates (primarily at 400mL/min).
The instructions given to the participants were to analyze the 2
platform assessment kits (Kits A and B) and theworkﬂowkit (Kit C)
by LC/MRM-MS or LC/PRM-MS. Each site performed interference
testing on the complete panel of 43 peptides, or used a smaller
panel of peptides as speciﬁed for their platform in the SOP, based
on prior testing. Those peptides that passed the interference
testing were targeted by MRM or PRM. The analysis order for the
standard samples was speciﬁed in the SOP as follows: Kit A–Kit
B–Kit A, then Kit A–Kit C–Kit A. Extracted ion chromatograms
(XICs) obtained for the target quantiﬁer peptides were compared
across the 4 measurements in Kit A and were used to generate
Table 2
Participants and instruments involved in the inter-laboratory standardization study of the platform/workﬂowQC assessment kits. The study included 19 LC–MS/MSplatforms
in 16 laboratories across 7 countries. General LC details were 0.2–0.4mL/min for nano-ﬂow and 0.2–0.4mL/min for standard-ﬂow, with an average of 3 or 1.8mm particles
packed onto columns of 50–100mm100–150mm for nano-ﬂow and 2.1100–150mm for standard-ﬂow. The reference instruments are labeled as site numbers R1a and
R1b. Complete platform details are provided in Supporting information—Methods.
Site No. Lab location General LC conditions Mass spectrometer
Flow type Chromatography Gradient
1 Country 1 Nano HPLC 60 QTRAP 5500
2 Country 1 Nano UHPLC 90 QTRAP 5500
3 Country 1 Nano HPLC 90 QTRAP 5500
4 Country 1 Nano HPLC 35 QTRAP 5500
5 Country 1 Nano HPLC 90 QTRAP 5500
6 Country 2 Standard UHPLC 30 QTRAP 5500
7 Country 3 Nano UHPLC 60 QTRAP 5500
8 Country 1 Nano HPLC 60 QTRAP 4000
9 Country 4 Standard HPLC 35 QTRAP 4000
10 Country 1 Nano UHPLC 71 Q Exactive
11 Country 5 Nano HPLC 51 Q Exactive
12a Country 6 Nano UHPLC 75 Q Exactive
12b Country 6 Standard UHPLC 30 6490
13 Country 4 Nano HPLC 60 6460
14 Country 3 Nano UHPLC 80 TSQ Vantage
15a Country 7 Nano HPLC 60 TSQ Vantage
15b Country 7 Standard UHPLC 35 Xevo TQ-S
R1a Canada Standard UHPLC 30 6490
R1b Canada Standard UHPLC 30 QTRAP 6500
[(Fig._2)TD$FIG]
Fig. 2. Number of peptides detected in Kit A from the 4 measurements. Plotted are
the results from all sites (including the 2 reference platforms) for the 8 differentMS
instruments utilized, with arrows to differentiate the standard-ﬂow LC systems
from the nano-ﬂow. Please see Supplemental Fig. 2 for a plot of the differences
between the peptides monitored and the peptides detected.
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peptide standard curves for quantitation in Kits B and C. The peak
veriﬁcation was done at each site, but the quantitation (for Kits B
and C) and data analysis (for all kits) was done at the UVic-Genome
BC Proteomics Centre using Qualis-SIS software [19] andMicrosoft
Excel.
3. Results and discussion
3.1. Peptide detection and metric comparison using Kit A
The purpose of Kit A is to help isolate LC–MS issues through the
monitoring of performance metrics over replicate injections. Here,
a total of 4 measurements were made (once before and once after
the use of Kits B and C), with the results used to evaluate system
performance. Although it seems intuitive that the use of a platform
with increased mass and chromatographic resolution would be
less subject to interferences than one with lower resolution (of
both types), as can be seen from Fig. 2, the number of reproducibly
detected peptides was not correlated with the use of a nano-ﬂow
or standard-ﬂow LC–MS/MS platform (see Supporting informa-
tion—Fig. 2 for the site differences between the peptides
monitored and detected). That this was not the case in this study
speaks to the accuracy of the interference testing – achieved
through ion ratio comparisons for each peptide’s top 3 precursor-
product ion pairs in buffer and matrix – that was done on these
particular proteotypic peptide standards,making them suitable for
use on a variety of instruments and platforms. To more closely
examine this rather unexpected, but very promising, ﬁnding, two
key performance metrics – retention time (RT, for LC evaluation)
and relative response (RR, for MS assessment) – were explored.
To best assess the performance of the LC systems, the RT
variability for a matching set of peptides was plotted for the 19 LC–
MS/MS platforms (includes the reference sites R1a and R1b)
according to the type of chromatography (HPLC vs UHPLC) and the
ﬂow rate (nano-ﬂow vs standard-ﬂow; see Fig. 3). Although lower
variability was obtained with the standard-ﬂow platforms (aver-
age %CVs were 0.20 with standard-ﬂow UHPLC and 0.61 with
standard-ﬂow HPLC vs 2.06 with nanoUHPLC and 2.16 with
nanoHPLC), sites 4 and 14 demonstrated that well-functioning
nanoLC–MS/MS platforms are also capable of providing compara-
bly low variabilities (average %CVs were 0.23 for site 4 and 0.28 for
site 14). In fact, the RT variability for all reproducibly detected
peptides at site 4 (36 peptides in total) and site 14 (39 peptides in
total) was 0.29 and 0.47 %CV, respectively. The outliers in the
dataset indicate a potential LC issue (e.g., a system leak, restricted
ﬂow) that should be corrected before any “real” analytical
measurements are made. To assist in this troubleshooting, column
pressure and ﬂow rate traces should be recorded as part of the
acquisition parameters since ﬂuctuations can reveal operation
errors (e.g., pressure dip – air bubble; improperly pulsing solvent
delivery system – bad check valve). Overall, although there is a
clear variation in both the distribution and the values of the RT %
CVs, the average %CV was 1.6% across all 19 LC–MS/MS platforms.
[(Fig._3)TD$FIG]
Fig. 3. Global RT variability comparisons of Kit A measured in quadruplicate across
the 19 LC–MS/MS platforms. The sites are sorted according to chromatography and
ﬂow rate for the same panel of reproducibly detected peptides. Additional LC–MS/
MS details and the origination sites (e.g., R1a and R1b denote the reference
instruments) are provided in Table 2 and Supporting information—Methods.
[(Fig._4)TD$FIG]
Fig. 4. Comparisons of RR variability for Kit Ameasured in quadruplicate across the
19 LC–MS/MS platforms. Variability comparisons for 7 laboratories using the QTRAP
5500 in a) and 3 laboratories using the Q-Exactive in b). c) Global variability
comparison across all measured platforms. Data from an independent set of
matching peptides is shown in each part, with each peptide’s RR variability shown
as blue diamonds and the average intra-site variability as red squares. As deﬁned in
Table 2, the reference instruments are labeled with site numbers R1a and R1b. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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To assess variability at the MS level, the average %CV in RR (i.e.,
the NAT/SIS peak area ratio, where NAT is deﬁned as the
endogenous peptide signal) for the quadruplicate measurements
was compared on a peptide-by-peptide basis. Here, data collected
from the same instrument was ﬁrst compared (Fig. 4a for the
QTRAP 5500s, Fig. 4b for the Q Exactives) before comparing the
global variability across all sites (Fig. 4c). Regarding the local
comparisons, Fig. 4a and b show unexpectedly high variability
(>20% CV) for certain sites that was independent of the instrument
employed (e.g., site 1 vs site 4 in Fig. 4a; site 11 vs site 10 in Fig. 4b).
This result was also observed in the global Fig. 4c plot when
examining the range and average RR variability with a smaller set
of matching peptides. Since the outliers had relatively stable RTs
(the exception being site 11), the cause for the variability is purely
MS-based (most likely due to interference with the transitions).
Regarding site 11, a serious technical issue occurred since the RTs
and RRs were both highly variable, with average %CVs of 8.6% and
118.3%, respectively, for their 11 reproducibly detected peptides.
Considering all sites, however, although therewas variation in both
the distribution and the value of the RR %CVs, the average %CV was
14.2%.
3.2. Quantitative performance evaluation with Kit B
Since quantitation was done using peptide standard curves
under strict qualiﬁcation criteria (which involve, for example,
precision and accuracy thresholds for the 5 replicates within a
given concentration level), the number of proteins quantiﬁed was
expected to be lower than would otherwise be expected based on
the relative response data alone. The observed reduction between
the number of detected and quantiﬁed peptides in Kits A and Kit B
was an average of 8. Fig. 5 shows the results from Kit B, with the
number of proteins quantiﬁed plotted as a function of instrument
used. Although there are too few instruments involved for a
rigorous statistical comparison, it appears that a major component
of the variability is within-instrument rather than between
instrument types. For instance, low sensitivity seems to be the
cause of the reduced quantitation of the apparent outliers at select
sites that utilized the QTRAP 4000 (site 9), Q Exactive (site 12a),
and TSQ Vantage (site 14) instruments. This is attributed to the fact
that the average dynamic range of the platforms utilizing those
instruments at those sites was only 1–2 orders of magnitude,
compared to the expected 3 orders of magnitude observed for the
reference sites as well as for site 8 (QTRAP 4000), site 11 (Q
Exactive), and site 15a (TSQ Vantage) using a matching set of
quantiﬁed proteins. RR variability with these outlier sites is an
additional issue that restricted the number of proteins quantiﬁed
through regression analysis of standard curves. For instance, 25
peptides from the site 9 data had RRCVs >>20% at the top 3 levels of
the curve (which reﬂect standards E, F, and G). Since these 3 upper
levels must pass our precision and accuracy criteria in our low-to-
high concentration removal strategy (deﬁned initially in [20]),
these peptides were automatically excluded by Qualis-SIS [19].
This provides an explanation for the large difference of 26 observed
between the quantiﬁed and detected peptides in the site 9 Kit B
analysis.
To further interpret the Fig. 5 results, the plasma protein
concentrations were evaluated by examining the distribution of %
CVs for the two instruments that were used by at least 3 sites (the
QTRAP 5500 and the Q Exactive), as shown in Fig. 6a. From this
ﬁgure, it is clear that the Q Exactive produced a greater proportion
of peptides with a higher %CV than the QTRAP 5500, with the
results from the QTRAP having a tighter distribution. For instance,
the average CV for alpha-1-antichymotrypsin (P01011) was 21% for
the LC–MS/MS platforms utilizing the Q Exactive, but 9% on the
QTRAP 5500. Its average concentration, however, was comparable
to the reference values with 148mg/mL and 134mg/mL obtained
for the QTRAP 5500s and Q Exactives, respectively, compared to
151mg/mL for the reference sites (R1a and R1b).
Closer examination of the distribution involved a site-by-site
comparison to the reference concentrations for accuracy assess-
ment. This revealed cases of both excellent and poor agreement.
Fig. 6b shows a representative example of good correlation with a
matching set of 28 plasma proteins. In fact, the excellent
correlation with the site 5 Kit B results extended beyond the
concentrations—the average coefﬁcient of determination (R2) was
0.990 vs 0.992 and the average RR variability for standard E was
3.8% vs 2.1% CV (for sites 5 and R1a, respectively, in both cases). The
exception was in the RT variability (0.55% vs 0.08% CV from site
R1a). The deviation in RT variability from the reference, however, is
not unreasonable nor unexpected for site 5, based on the Kit A
results from their nano HPLC/MRM-MS platform relative to the
reference R1a values obtained on a standard-ﬂow UHPLC/MRM-
MS platform (Fig. 3).
A contrasting example is shown in Fig. 6c for site 12a (measured
by nanoLC/PRM-MS on a Q Exactive). Here, the derived concen-
trations for 11matching proteins showed poor agreement with the
reference site due to a consistently low linear dynamic range—an
average of one order of magnitude for these 11 proteins instead of
the expected 3 orders of magnitude. For instance, the quantiﬁer
peptide for apolipoprotein E had a dynamic range of 10 at the
reference site, compared to a dynamic range of 1000 at site 12a,
despite comparable R2 values (0.992 from site 12a vs 0.994 from
the reference sites R1a and R1b). The cause is attributed to sub-
optimal performance of the mass spectrometer, since 8 peptides
could not be observedwith standard E (which should have resulted
in balanced RRs of approximately 1:1) and 11 peptides had high RR
variability (>20% CV) at the 3 highest concentration levels, thus
preventing the generation of standard curves. These problems
were not observed with the other Q Exactives (e.g., site 10, where
the average dynamic range for the same peptides was 3 orders of
magnitude). This conﬁrms a problem in the performance of this
particular instrument at site 12a.
To assess the accuracy on a global scale, the proteins quantiﬁed
on all 19 LC–MS/MS platforms were compared (see Supporting
[(Fig._5)TD$FIG]
Fig. 5. Number of proteins quantiﬁed in Kit B by LC/MRM-MS or LC/PRM-MS as a
function of instrument employed. The reference and external platforms are colour
coded for comparison. The quantiﬁed values were obtained from Qualis-SIS using
global, default parameters (e.g., 1/x2 regression weighting, low-to-high concentra-
tion removal strategy, <20% deviation in a given levels precision and accuracy for
the 5 technical replicates).
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information Fig. 3a for a graphical overview). The quantitative
comparison of 4 moderate abundance proteins (reference concen-
tration range: 21–480mg/mL) is shown in Fig. 7. As can be seen
from this ﬁgure, the site-determined concentrationswere typically
within the acceptable accuracy limits of the reference values. Two
exceptions were hemopexin from site 12a and transthyretin from
site 7. In the former case, for example, poor linearity of the standard
curve (y-intercept: 0.179, R2: 0.974) contributed to this problem,
[(Fig._6)TD$FIG]
Fig. 6. Quantitative result comparisons from the LC/MRM-MS or LC/PRM-MS analysis of Kit B. a) Distribution of measured plasma protein concentration CVs for the QTRAP
5500 and the Q Exactive instruments against a common set of instrument-speciﬁc quantiﬁed proteins. To illustrate site-speciﬁc extremes, part b) shows an example of results
from site 5 that correlated well to the reference values, whereas part c) shows poor agreement of site 12a’s results with the references.
[(Fig._7)TD$FIG]
Fig. 7. Global quantitative comparisons from the LC–MS/MSmeasurement of Kit B. Accuracy assessment of 4moderate-abundance plasma proteins (concentration range: 21–
480mg/mL) against their corresponding reference values (notedwith dotted lines,20% accuracy limits shown as dotted plus signs), as determined by reference site R1a. The
quantitation values correspond to hemopexin (purple circles), alpha-1B-glycoprotein (green triangles), transthyretin (red squares), and plasma retinol-binding protein (blue
diamonds). Site details are provided in Table 2 and Supporting information—Methods. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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despite acceptable precision in RR and RT curve CVs. Overall, the
correlation with the reference values was not dependent on the
protein abundance level. For example, the high-abundance
proteins haptoglobin (average determined concentration:
1.3mg/mL) and apolipoprotein A–I (average determined concen-
tration: 0.8mg/mL) returned average inter-site CVs of 9.5% and
14.2%, respectively. This variability compared well to that of lower
abundance proteins in the dataset, such as L-selectin (average
determined concentration: 1.1mg/mL) and plasminogen (average
determined concentration: 5.1mg/mL), which gave average inter-
site CVs of 13.6% and 10.7% CV, respectively.
In further assessing the quantitative accuracy with Kit B, after
excluding 3 outliers (as determined by Grubbs test at the 97.5%
conﬁdence interval [21]), the average inter-site variability in
concentration across the 35 quantiﬁed proteins measured by at
least 3 LC–MS/MS platforms was found to be 16.5% CV. Compli-
ment C3, we note, had the lowest variability at 4.9% CV measured
across 15 platforms. Its determined concentration of 293mg/mL
correlates well with our previous determinations in other projects
using similar plasma lots and sample preparation protocols
[22,23]. In fact, the measured concentrations for the reference
are within 1.5-fold of those found previously, which strengthens
the accuracy assessments. Overall, the strong correlation of the
inter-site results was not unexpected since Kit B required only
rehydration before sample processing, which limited the potential
sources of variability. These results highlight the beneﬁt of an
optimally performing LC–MS/MS platform for maximum quanti-
tative output and optimal quantitative accuracy. It also reinforced
the utility of this kit for assessing LC–MS/MS platformperformance
and revealing the cause(s) of atypical variation.
3.3. Detection of procedural or instrumental errors with Kit C
As expected, sample preparation at the individual sites with Kit
C resulted in larger variability in the number of proteins quantiﬁed
than the results obtained by simply processing the centrally
prepared standards in Kit B (Fig. 8a vs. Fig. 5, also Supporting
information Fig. 3a vs 3b). Excluding the reference measurements,
the total number of proteins quantiﬁedwas reduced byaminimum
of 1 (with sites 2, 10, and 15b being at the low end), while peptide
detection using Kit A and quantitation in Kit C differed by a
minimum of 4 (with sites 2 and 15b being at the low end).
The most evident outliers in Fig. 8 were the ones that failed to
quantify a single proteinwith Kit C. In the case of the one circled in
red, for example, the cause for this anomaly was due to both
technician error and other errors (Fig. 8b). Regarding the former,
the user seems to have inadvertently switched the labels of
standards F and G prior to sample processing and analysis. This
resulted in the representative plots shown in the ‘Before Revision’
panel of Fig. 8b. Subsequent correction of the user-supplied
peptide input ﬁle prior to automated quantitation in Qualis-SIS
enabled the quantitation of 14 plasma proteins (see the standard
curve in the ‘After Revision’ panel of Fig. 8b for a representative
example). While deviation from the standardized protocol at the
trypsin solubilization step seems to have led to a problem with
tryptic digestion efﬁciency (average NAT response: 5.5E + 05 for Kit
C vs 6.6E + 06 for Kit B for a matching set of peptides), the number
[(Fig._8)TD$FIG]
Fig. 8. Quantitative results from the QC workﬂow performance Kit C. a) Total number of proteins quantiﬁed on the 19 LC–MS/MS platforms measured across the 16 sites
(external and internal). The colored circles represent the results from3 different sites. b) Example of technician and other errors in the “red site’s” results. c) Comparison of the
quantitation results for Kit C from the yellow and green sites with a matching set of reference values, as well as each site’s Kit C results with their values measured with Kit B.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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of detectable peptides in Kit C relative to Kit B was the same at 29.
The number of detectable peptides in Kit C relative to Kit B was the
same at 29, yielding an average NAT response of 5.5E +05 vs
6.6E + 06, respectively. Evidence of sub-optimal quantitative
performance was revealed by poor precision (>20% CV; see the
middle row of Fig. 8b) and the absence of complete technical
replicate data (see the bottom row of Fig. 8b) in at least 1 of the 3
highest concentration levels of Kit C’s standards. This caused their
immediate disqualiﬁcation, due to the violation of 3 qualiﬁcation
criteria (namely, the inclusion of all 5 replicates per level, a 20% CV
threshold in a given level’s precision, and the presence of 3
consecutive concentration levels). Upon closer examination of the
calibration curve data, the RT variability was low with the user-
prepared standards in Kit C (average CVs: 0.31% from standard E)
and correlated well with the variability obtained with Kit A
(average CVs: 0.82%, both for 26 matched peptides). This site also
experienced a larger-than-expected RR variability of 18.6% CV, on
average, from the Kit A analysis, which would also alert the user to
an instrument problem. To place this high variability into
perspective, site 2 and site 4 (both with nanoLC-MS/MS on a
QTRAP 5500) had average CVs in RR of <6%, as expected, for a
matching set of detectable peptides from Kit A.
Sub-optimal mass spectrometer performance was also the
cause for poor quantitation at some other sites in Fig. 8 (e.g., site 14,
nanoUHPLC/MRM-MS on the TSQ Vantage), while procedural
errors were the apparent cause of problems at site 9. In the latter
case, an error was made in the preparation of the SIS peptide
dilution series, as inferred from the incorrect SIS peptide ratios
obtained for the 3 highest concentration levels of the standard
curve (average ratios from standard G for Kit C vs Kit B: 1:5:6 vs the
expected 1:2:5). This explains the narrow dynamic range observed
with Kit C, as compared to the Kit B analysis (average dynamic
range: 20 vs 885) at the same site. In contrast, when the procedures
were carefully followed and the LC–MS/MS platformwas perform-
ing optimally, accurate and reproducible quantitation was
achieved (sites 3 and 7 in Fig. 8c). This good correlation extended
beyond the concentrations. For example, the average curve R2
values (from the relative response vs SIS peptide concentration
plots) for the proteins shown in Fig. 8c were 0.967 and 0.993 for
sites 3 and 7, respectively, compared to 0.994 from the references.
Evidence of their well-functioning LC/MRM-MS platforms also
came from the low RT and RR variabilities—the averages for these
two sites were 3.9% and 2.1% CV for RR, and 0.61% and 0.15% CV for
RT, both derived from standard E replicate data. This compared
well to their Kit B results, which showed an average variability of
4.3% and 2.1% CV in RR, with 0.99% CV and 0.13% CV being obtained
for RT (again with standard E replicate curve data). Since the kits
were processed several weeks apart, the low degree of variability
obtained with the site 3 and 7 data demonstrates the stability of
their LC/MRM-MS platforms over that time period.
Also instructive is the global quantitative accuracy assessment
of the Kit Cmeasurements (see Supporting information Fig. 2b for a
graphical overview and Fig. 9 for a quantitative comparison). As
illustrated in Fig. 9, the majority of the determined concentrations
for apolipoprotein E were within the accuracy limits of quantita-
tion, the exception being site 5. This outlier site also generated
concentrations that lay outside the accuracy limits of heparin
cofactor II. Since their derived concentrations were below the
lower accuracy limit for these proteins, as well as others not
depicted in this ﬁgure (e.g., 12mg/mL determined for inter-alpha-
trypsin inhibitor heavy chain H1 vs 36–44mg/mL for the references
with an accuracy range of 29–52mg/mL), the cause is attributed to
inefﬁcient proteolytic digestion. This explanation can also be
applied to other outlier sites in Fig. 9 that demonstrated acceptable
assay attributes and performance metrics (e.g., sites 8 and 15a).
Nonetheless, the average inter-site variabilities for heparin
cofactor II and apolipoprotein E were found to be 16.1% and
17.9% CV, respectively. These variabilities compared well to those
obtained with Kit B (average inter-site CVs of 11.7% for heparin
cofactor II and 19.6% for apolipoprotein E), with similar average
concentrations (45.3 and 21.6mg/mL for heparin cofactor II and
apolipoprotein E, respectively, with Kit C vs. 49.2 and 23.9mg/mL
for these 2 proteins with Kit B).
Overall, this study reinforced the value of these kits for routine
and comprehensive performance assessment. This study also
emphasized the importance of carrying out this performance
assessment in order to reveal the absence or presence of a
procedural or instrumental error that would need to be corrected
prior to performing a set of “real” quantitation experiments
4. Conclusions and future considerations
Standardization of proteomic methods and analytical platforms
is essential for precise and accurate protein quantitation within
and between laboratories. To this end, we have developed three
standardization kits (A and B for platform assessment, C for
complete workﬂow) for routine and comprehensive evaluation of
various phases of an MRM-with-SIS-peptide assay. In this study,
these three QC assessment kits (prepared at the UVic-Genome BC
Proteomics Centre) were evaluated on 17 LC–MS/MS platforms
across 15 external laboratories spanning 5 continents. The overall
conclusions drawn from this study, which involved the quantita-
tion of 43 plasma proteins in non-depleted human plasma, were
that these 3 performance assessment kits can be successfully used
[(Fig._9)TD$FIG]
Fig. 9. Global quantitative accuracy comparisons using Kit C, as measured by 17 external LC–MS/MS platforms. Two moderate-abundance plasma proteins. quantiﬁed by a
minimum of 11 platforms, are shown against their corresponding reference values (noted with dotted lines,20% accuracy limits shown as dotted plus signs), as determined
by reference site R1a. The quantitation values correspond to heparin cofactor II (green triangles) and apolipoprotein E (purple circles). Site details are provided in Table 2 and
Supporting information—Methods. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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to evaluate laboratory procedures and platform performance,
thereby enabling corrective methods or systemmaintenance to be
undertaken. This study further showed that the accuracy of protein
quantitation was independent of the LC–MS/MS platform, when
performing optimally, but was dependent on the technical skills of
the individual user.
The next step in this global standardization process involves
training the users when errors were noted (be it from a sample
preparation or LC–MS/MS processing), and then repeating the
study to determine whether the quantitative accuracy and
reproducibility can be improved. This study also highlighted the
value of developing fully automated sample preparation proce-
dures if MS-based assays are to ﬁnd widespread clinical
implementation. An additional consideration involves working
with the instrument vendors toward the development of
automated software solutions for system suitability. This will
help non-expert users rapidly diagnose platform errors, which
might arise unexpectedly during routine use. In this type of
software, if the speciﬁcations for a given standard, such as QC Kit A,
are not satisﬁed over replicate injections (due to either chro-
matographic properties such as column pressure, ﬂow stability,
and peak symmetry, or mass spectrometric performance issues
such as electrospray stability, sensitivity, and MS/MS fragmenta-
tion), then the batchwould be automatically aborted and the cause
for this action would be reported in a transmission log. Such
automated QA/QC measures are imperative for non-expert use of
proteomic methods and for the use LC–MS/MS platforms in the
clinic. Implementation of these procedures will also help to
improve the quantitative reproducibility and accuracy of large-
scale proteomic efforts, such as protein biomarker screening.
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